EGFR and EGFR ligands in serum in healthy women; reference intervals and age dependency

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

The epidermal growth factor receptor (EGFR) system is involved in cancer pathogenesis and serves as an important target for multiple cancer treatments. EGFR and its ligands epidermal growth factor (EGF), heparin-binding epidermal growth factor (HB-EGF), betacellulin (BTC), amphiregulin (AREG) and transforming growth factor α (TGF-α) have potential applications as prognostic or predictive serological biomarkers in cancer. The aim was to establish EGFR and EGFR ligand reference intervals in healthy women. EGFR and EGFR ligands were measured in serum from 419 healthy women aged 26-78 years. The need for age partitioned reference intervals was evaluated using Lahti's method. EGFR and EGF were analyzed using ELISA assays, whereas HB-EGF, BTC, AREG and TGF-α were analyzed using the highly sensitive automated single molecule array (Simoa) enabling detection below the lower reference limit for all six biomarkers. Reference intervals for EGFR and the EGFR ligands were determined as the 2.5th and 97.5th percentiles. All six biomarkers were detectable in all serum samples. For EGFR, EGF, HB-EGF and TGF-α, reference intervals were established for women <55 years and for women >55 years, whilst common reference intervals were established for AREG and BTC including women aged 26-78 years. Age specific reference intervals were determined for EGFR, EGF, HB-EGF, BTC, AREG and TGF-α.

Original languageEnglish
JournalClinical Chemistry and Laboratory Medicine
ISSN1434-6621
DOIs
Publication statusE-pub ahead of print - 16. Jul 2019

Fingerprint

Epidermal Growth Factor Receptor
Epidermal Growth Factor
Ligands
Serum
Transforming Growth Factors
Heparin
Biomarkers
Oncology
Assays
Neoplasms
Molecules
Amphiregulin
Betacellulin

Keywords

  • cancer biomarkers
  • epidermal growth factor receptor
  • epidermal growth factor receptor ligands
  • reference interval
  • serum

Cite this

@article{c3be4c24158e4e85ac115f59aedbc957,
title = "EGFR and EGFR ligands in serum in healthy women; reference intervals and age dependency",
abstract = "The epidermal growth factor receptor (EGFR) system is involved in cancer pathogenesis and serves as an important target for multiple cancer treatments. EGFR and its ligands epidermal growth factor (EGF), heparin-binding epidermal growth factor (HB-EGF), betacellulin (BTC), amphiregulin (AREG) and transforming growth factor α (TGF-α) have potential applications as prognostic or predictive serological biomarkers in cancer. The aim was to establish EGFR and EGFR ligand reference intervals in healthy women. EGFR and EGFR ligands were measured in serum from 419 healthy women aged 26-78 years. The need for age partitioned reference intervals was evaluated using Lahti's method. EGFR and EGF were analyzed using ELISA assays, whereas HB-EGF, BTC, AREG and TGF-α were analyzed using the highly sensitive automated single molecule array (Simoa) enabling detection below the lower reference limit for all six biomarkers. Reference intervals for EGFR and the EGFR ligands were determined as the 2.5th and 97.5th percentiles. All six biomarkers were detectable in all serum samples. For EGFR, EGF, HB-EGF and TGF-α, reference intervals were established for women <55 years and for women >55 years, whilst common reference intervals were established for AREG and BTC including women aged 26-78 years. Age specific reference intervals were determined for EGFR, EGF, HB-EGF, BTC, AREG and TGF-α.",
keywords = "cancer biomarkers, epidermal growth factor receptor, epidermal growth factor receptor ligands, reference interval, serum",
author = "Kj{\ae}r, {Ina Mathilde} and Olsen, {Dorte Aalund} and Anne Alnor and Ivan Brandslund and Troels Bechmann and Madsen, {Jonna Skov}",
year = "2019",
month = "7",
day = "16",
doi = "10.1515/cclm-2019-0376",
language = "English",
journal = "Clinical Chemistry and Laboratory Medicine",
issn = "1434-6621",
publisher = "Walterde Gruyter GmbH",

}

TY - JOUR

T1 - EGFR and EGFR ligands in serum in healthy women; reference intervals and age dependency

AU - Kjær, Ina Mathilde

AU - Olsen, Dorte Aalund

AU - Alnor, Anne

AU - Brandslund, Ivan

AU - Bechmann, Troels

AU - Madsen, Jonna Skov

PY - 2019/7/16

Y1 - 2019/7/16

N2 - The epidermal growth factor receptor (EGFR) system is involved in cancer pathogenesis and serves as an important target for multiple cancer treatments. EGFR and its ligands epidermal growth factor (EGF), heparin-binding epidermal growth factor (HB-EGF), betacellulin (BTC), amphiregulin (AREG) and transforming growth factor α (TGF-α) have potential applications as prognostic or predictive serological biomarkers in cancer. The aim was to establish EGFR and EGFR ligand reference intervals in healthy women. EGFR and EGFR ligands were measured in serum from 419 healthy women aged 26-78 years. The need for age partitioned reference intervals was evaluated using Lahti's method. EGFR and EGF were analyzed using ELISA assays, whereas HB-EGF, BTC, AREG and TGF-α were analyzed using the highly sensitive automated single molecule array (Simoa) enabling detection below the lower reference limit for all six biomarkers. Reference intervals for EGFR and the EGFR ligands were determined as the 2.5th and 97.5th percentiles. All six biomarkers were detectable in all serum samples. For EGFR, EGF, HB-EGF and TGF-α, reference intervals were established for women <55 years and for women >55 years, whilst common reference intervals were established for AREG and BTC including women aged 26-78 years. Age specific reference intervals were determined for EGFR, EGF, HB-EGF, BTC, AREG and TGF-α.

AB - The epidermal growth factor receptor (EGFR) system is involved in cancer pathogenesis and serves as an important target for multiple cancer treatments. EGFR and its ligands epidermal growth factor (EGF), heparin-binding epidermal growth factor (HB-EGF), betacellulin (BTC), amphiregulin (AREG) and transforming growth factor α (TGF-α) have potential applications as prognostic or predictive serological biomarkers in cancer. The aim was to establish EGFR and EGFR ligand reference intervals in healthy women. EGFR and EGFR ligands were measured in serum from 419 healthy women aged 26-78 years. The need for age partitioned reference intervals was evaluated using Lahti's method. EGFR and EGF were analyzed using ELISA assays, whereas HB-EGF, BTC, AREG and TGF-α were analyzed using the highly sensitive automated single molecule array (Simoa) enabling detection below the lower reference limit for all six biomarkers. Reference intervals for EGFR and the EGFR ligands were determined as the 2.5th and 97.5th percentiles. All six biomarkers were detectable in all serum samples. For EGFR, EGF, HB-EGF and TGF-α, reference intervals were established for women <55 years and for women >55 years, whilst common reference intervals were established for AREG and BTC including women aged 26-78 years. Age specific reference intervals were determined for EGFR, EGF, HB-EGF, BTC, AREG and TGF-α.

KW - cancer biomarkers

KW - epidermal growth factor receptor

KW - epidermal growth factor receptor ligands

KW - reference interval

KW - serum

U2 - 10.1515/cclm-2019-0376

DO - 10.1515/cclm-2019-0376

M3 - Journal article

JO - Clinical Chemistry and Laboratory Medicine

JF - Clinical Chemistry and Laboratory Medicine

SN - 1434-6621

ER -